Arkolith/Insider Trading/SNDX/Form 4

Botwood Nicholas A.J.

Head of R&D, CMOSyndax Pharmaceuticals Inc (SNDX) · full profile →Form 4 · filed Jun 12, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$1.2M
Net Open-Market Flow
-$1.2M
Transactions
6
4 non-derivative · 2 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jun 12, 2026Option exercise(M)31K$13.82$432K92K
Jun 12, 2026Sell(S)31K$18.14$567K61K
Jun 11, 2026Option exercise(M)23K$13.82$311K95K
Jun 11, 2026Sell(S)34K$18.00$617K61K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jun 12, 2026Option exercise(M)31K—$00
Jun 11, 2026Option exercise(M)23K—$00

Transaction Codes

M
Option exercise / conversion
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001193125-26-269694) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML